Column

Viewpoint

The CAR-T Breakthrough: More Than Just Another Treatment Option

04/17/2018

Winston Wong, PharmD, Editor-in-Chief

The ability to rewire human immune systems to fight cancer is certainly an exciting prospect. With the first 2 chimeric antigen receptor T-cell (CAR-T) therapies approved and over 200 more in clinical trials,...

The...

04/17/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Dealing With New Formulary Types: Health System Outpatient Formularies

04/17/2018

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Developers and utilizers of clinical pathways need to understand that formulary systems encompass more than merely a list of medications approved by a managed care organization. These stakeholders should also factor...

...

04/17/2018

Journal of Clinical Pathways

Pharma Insights

Economic Assessment of Novel Gene and Cellular Therapies: Beyond Traditional Modeling

04/17/2018

Philip Cyr, MPH

Larry Blandford, PharmD—Column Editor

Various forms of decision health analytic modeling have been used for the last 3 decades to assess potential health economic impact of new therapies. As initial gene and cellular therapies come to market, debate is...

...

04/17/2018

Journal of Clinical Pathways

Editor's Page

Working Together to Ensure Patient Access to Clinical Advancements

04/17/2018

Winston Wong, PharmD, Editor-in-Chief

It is an exciting time in oncology care as innovative cellular and gene therapies come to market, with many more to come in the near future. While the promise of these therapies is certainly cause for enthusiasm,...

It is...

04/17/2018

Journal of Clinical Pathways

PATIENT PERSPECTIVE

The Time Has Come to Involve Patients in Clinical Pathways

03/15/2018

Alan Balch, PhD—Column Editor

Patients are not often given a voice in the development and implementation of clinical pathways, the main focus of which have been to provide treatment options and guidance primarily based on clinical medical...

...

03/15/2018

Journal of Clinical Pathways

Pharma Insights

What Changes When Medicine Goes Digital?

03/15/2018

Amanda Lever, BSc

Auralyn MacKenzie, BSc

Larry Blandford, PharmD—Column Editor

Health care has become increasingly digitalized, but until now drugs have escaped digitalization. Advancements in digital technologies are changing how we think about disease management and even disease treatment....

Health...

03/15/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Targeting the Quadruple Aim Through Clinical Pathways

03/15/2018

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

All health care professionals recognize the Triple Aim, which is focused on outcomes, costs, and patient experiences. However, a fourth aim was added, which focuses on an essential, yet often forgotten, contribution...

All...

03/15/2018

Journal of Clinical Pathways

Editor's Page

Preserving Patient and Provider Voice in Clinical Pathway Development and Use

03/15/2018

Winston Wong, PharmD, Editor-in-Chief

In our increasingly digital world, providers’ and patients’ voices and individual needs must be prioritized. When it comes to treating others or being treated for incredibly complex illnesses, the health and...

In our...

03/15/2018

Journal of Clinical Pathways

Pharma Insights

How Variations in Health Systems Influence Oncology Practices

02/15/2018

Ashwin Athri, MBA

Changing marketplace dynamics related to the demographics and economics of cancer care is making it necessary for health systems to adapt and invest in capabilities ranging from care coordination models to a...

...

02/15/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Who Really Controls Treatment Selection? It`s Not Always Who You Think

02/15/2018

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

New policies and legislation related to health care reform mean that control over treatment selections may also shift within different markets. For professionals creating a clinical pathway for a disease state, it is...

New...

02/15/2018

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Column

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products